Helmholtz Gemeinschaft


COVID19-associated cardiomyocyte dysfunction, arrhythmias and the effect of Canakinumab

PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader

Item Type:Article
Title:COVID19-associated cardiomyocyte dysfunction, arrhythmias and the effect of Canakinumab
Creators Name:Dimai, S. and Semmler, L. and Prabhu, A. and Stachelscheid, H. and Huettemeister, J. and Klaucke, S.C. and Lacour, P. and Blaschke, F. and Kruse, J. and Parwani, A. and Boldt, L.H. and Bullinger, L. and Pieske, B.M. and Heinzel, F.R. and Hohendanner, F.
Abstract:BACKGROUND: Cardiac injury associated with cytokine release frequently occurs in SARS-CoV-2 mediated coronavirus disease (COVID19) and mortality is particularly high in these patients. The mechanistic role of the COVID19 associated cytokine-storm for the concomitant cardiac dysfunction and associated arrhythmias is unclear. Moreover, the role of anti-inflammatory therapy to mitigate cardiac dysfunction remains elusive. AIMS AND METHODS: We investigated the effects of COVID19-associated inflammatory response on cardiac cellular function as well as its cardiac arrhythmogenic potential in rat and induced pluripotent stem cell derived cardiomyocytes (iPS-CM). In addition, we evaluated the therapeutic potential of the IL-1β antagonist Canakinumab using state of the art in-vitro confocal and ratiometric high-throughput microscopy. RESULTS: Isolated rat ventricular cardiomyocytes were exposed to control or COVID19 serum from intensive care unit (ICU) patients with severe ARDS and impaired cardiac function (LVEF 41±5%; 1/3 of patients on veno-venous extracorporeal membrane oxygenation; CK 154±43 U/l). Rat cardiomyocytes showed an early increase of myofilament sensitivity, a decrease of Ca(2+) transient amplitudes and altered baseline [Ca(2+)] upon exposure to patient serum. In addition, we used iPS-CM to explore the long-term effect of patient serum on cardiac electrical and mechanical function. In iPS-CM, spontaneous Ca(2+) release events were more likely to occur upon incubation with COVID19 serum and nuclear as well as cytosolic Ca(2+) release were altered. Co-incubation with Canakinumab had no effect on pro-arrhythmogenic Ca(2+) release or Ca(2+) signaling during excitation-contraction coupling, nor significantly influenced cellular automaticity. CONCLUSION: Serum derived from COVID19 patients exerts acute cardio-depressant and chronic pro-arrhythmogenic effects in rat and iPS-derived cardiomyocytes. Canakinumab had no beneficial effect on cellular Ca(2+) signaling during excitation-contraction coupling. The presented method utilizing iPS-CM and in-vitro Ca(2+) imaging might serve as a novel tool for precision medicine. It allows to investigate cytokine related cardiac dysfunction and pharmacological approaches useful therein.
Keywords:Cardiac Arrhythmias, Cardiac Myocytes, COVID-19, Calcium, Calcium Signaling, Humanized Monoclonal Antibodies, Induced Pluripotent Stem Cells, Left Ventricular Dysfunction, Preclinical Drug Evaluation, SARS-CoV-2, Sprague-Dawley Rats, Animals, Rats
Source:PLoS ONE
Publisher:Public Library of Science
Page Range:e0255976
Date:19 August 2021
Official Publication:https://doi.org/10.1371/journal.pone.0255976
PubMed:View item in PubMed

Repository Staff Only: item control page


Downloads per month over past year

Open Access
MDC Library